Hans-Georg Rammensee

Rammensee studied Biology at the University of Tübingen and worked as a PhD student at the Max Planck Institute for Biology in Tübingen. After gaining his doctorate in 1982 he initially worked as a post-doctoral research fellow at Scripps Research Institute, La Jolla, USA. In 1985 he moved as a scientific member to the Basel Institute for Immunology, Basel, Switzerland. Two years later Rammensee returned to Max Planck Institute for Biology as a group leader at the department of immunogenetics. 1993 he became head of department at the Tumor-Virus-Immunology Section of the German Cancer Research Center, Heidelberg, Germany. The same year he was appointed professor at the Faculty of Theoretical Medicine of Heidelberg University. He has been a Full Professor at the University of Tübingen and Chair of the Department of Immunology at the Institute for Cell Biology since 1996.{{cite web|url=http://www.immunology-tuebingen.de/home.html|title=Home|website=Immunology-tuebingen.de|access-date=10 December 2017}}

==Research==

Since the late 1970s, Rammensee has been focusing on immunology with the specific aim of using tumor immunology to fight against cancer. He has contributed to genetics and immune regulation as well as to the understanding of minor H antigens, T cells and the major histocompatibility complex (MHC). His group has systematically developed bioinformatics tools for this purpose. In recent years, Rammensee has combined basic research on MHC biology with translational research, thus bringing tumor immunology into clinical practice. Currently he is focusing on the development of individualized cancer immunotherapy.

In 2000 and 2010, Rammensee co-founded three research-based companies. Immatics is involved in the development of cancer immunotherapies,{{cite web|url=http://immatics.com/company.html|title=Company – Immatics|website=immatics.com|access-date=10 December 2017}} CureVac develops therapies based on messenger RNA (mRNA);{{cite web|url=http://www.curevac.com/company/|title=curevac.de: Company|website=Curevac.com|access-date=10 December 2017}} synimmune on recombinant antibodies.{{cite web|url=http://www.synimmune.de/welcome/|title=SYNIMMUNE GmbH: Welcome|website=Synimmune.de|access-date=10 December 2017}}

• Ernst Jung Prize for Medicine, 2016{{cite web|url=http://www.jung-stiftung.de/de/ausgezeichnete-medizin/ernst-jung-preis-fuer-medizin/2016/preistraeger-216.html|title=Professor Hans-Georg Rammensee — Deutsch|website=Jung-stiftung.de|access-date=10 December 2017}}
• German Cancer Aid Award, 2013{{cite web|url=https://www.dkfz.de/en/presse/pressemitteilungen/2014/dkfz-pm-14-06b-DKTK-Hans-Georg-Rammensee-receives-2013-German-Cancer-Aid-Award.php|title=DKTK Tübingen: Hans-Georg Rammensee receives 2013 German Cancer Aid Award|website=Dkfz.de|access-date=10 December 2017}}
• Hansen Family Award, 2013{{cite web|url=http://www.bayer-foundations.com/en/hansen-family-award.aspx|title=Bayer AG – Stiftungen|first=Bayer AG|last=Communications|website=Bayer-foundations.com|access-date=10 December 2017|archive-date=27 September 2018|archive-url=https://web.archive.org/web/20180927024706/http://www.bayer-foundations.com/en/hansen-family-award.aspx|url-status=dead}}
• Advanced Grant of the European Research Council, 2013{{cite web|url=http://cordis.europa.eu/project/rcn/188495_en.html|title=European Commission : CORDIS : Projects and Results : Mutation-driven immunoediting of human cancer?|website=cordis.europa.eu|access-date=10 December 2017}}
• Paul Ehrlich and Ludwig Darmstaedter Prize, 1996{{cite web|url=https://www.uni-frankfurt.de/44556747/preistraeger|title=Goethe-Universität — Preisträger seit 1952|website=Uni-frankfurt.de|access-date=10 December 2017}}
• Robert Koch Prize, 1993{{cite web|url=http://www.robert-koch-stiftung.de/index.php?article_id=170&clang=1|title=Robert Koch Stiftung – Hans-Georg Rammensee|website=Robert-koch-stiftung.de|access-date=10 December 2017}}
• Gottfried Wilhelm Leibniz Prize, 1992{{cite web|url=https://www.dfg.de/download/pdf/gefoerderte_projekte/preistraeger/gwl-preis/leibniz_preistraeger_86_17.pdf|title=Liste der Leibniz-Preisträger 1986 – 2017|website=Dfg.de|access-date=10 December 2017|archive-date=12 March 2017|archive-url=https://web.archive.org/web/20170312073709/https://www.dfg.de/download/pdf/gefoerderte_projekte/preistraeger/gwl-preis/leibniz_preistraeger_86_17.pdf|url-status=dead}}
• Heinz Maier Leibnitz Prize, 1988{{cite web|url=https://www.dfg.de/download/pdf/gefoerderte_projekte/preistraeger/hml-preis/leibnitz_preistraeger_78_17.pdf|title=Liste der Heinz Maier-Leibnitz-Preisträger 1978 bis 2017|website=Dfg.de|access-date=10 December 2017}}

{{Scholia}}

• Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114.{{cite journal|title=The immunopeptidomic landscape of ovarian carcinomas|first1=Heiko|last1=Schuster|first2=Janet K.|last2=Peper|first3=Hans-Christian|last3=Bösmüller|first4=Kevin|last4=Röhle|first5=Linus|last5=Backert|first6=Tatjana|last6=Bilich|first7=Britta|last7=Ney|first8=Markus W.|last8=Löffler|first9=Daniel J.|last9=Kowalewski|first10=Nico|last10=Trautwein|first11=Armin|last11=Rabsteyn|first12=Tobias|last12=Engler|first13=Sabine|last13=Braun|first14=Sebastian P.|last14=Haen|first15=Juliane S.|last15=Walz|first16=Barbara|last16=Schmid-Horch|first17=Sara Y.|last17=Brucker|first18=Diethelm|last18=Wallwiener|first19=Oliver|last19=Kohlbacher|first20=Falko|last20=Fend|first21=Hans-Georg|last21=Rammensee|first22=Stefan|last22=Stevanović|first23=Annette|last23=Staebler|first24=Philipp|last24=Wagner|date=14 November 2017|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=114|issue=46|pages=E9942–E9951|doi=10.1073/pnas.1707658114|pmid=29093164|pmc=5699044|bibcode=2017PNAS..114E9942S |doi-access=free}}
• Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29.{{cite journal|title=HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)|first1=Daniel J.|last1=Kowalewski|first2=Heiko|last2=Schuster|first3=Linus|last3=Backert|first4=Claudia|last4=Berlin|first5=Stefan|last5=Kahn|first6=Lothar|last6=Kanz|first7=Helmut R.|last7=Salih|first8=Hans-Georg|last8=Rammensee|first9=Stefan|last9=Stevanovic|first10=Juliane Sarah|last10=Stickel|date=13 January 2015|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=112|issue=2|pages=E166–175|doi=10.1073/pnas.1416389112|pmid=25548167|pmc=4299203|bibcode=2015PNAS..112E.166K |doi-access=free}} Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6258-60.{{cite journal|title=Correction to Supporting Information for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)|date=10 November 2015|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=112|issue=45|pages=E6258–6260|doi=10.1073/pnas.1519136112|pmid=26527660|pmc=4653161|bibcode=2015PNAS..112E6258. |doi-access=free}} Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6{{cite journal|title=Correction for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)|date=10 November 2015|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=112|issue=45|pages=E6254–6256|doi=10.1073/pnas.1519135112|pmid=26483495|pmc=4653212|bibcode=2015PNAS..112E6254. |doi-access=free}}
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988{{cite journal|title=Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens|first1=Matthew M.|last1=Gubin|first2=Xiuli|last2=Zhang|first3=Heiko|last3=Schuster|first4=Etienne|last4=Caron|first5=Jeffrey P.|last5=Ward|first6=Takuro|last6=Noguchi|first7=Yulia|last7=Ivanova|first8=Jasreet|last8=Hundal|first9=Cora D.|last9=Arthur|first10=Willem-Jan|last10=Krebber|first11=Gwenn E.|last11=Mulder|first12=Mireille|last12=Toebes|first13=Matthew D.|last13=Vesely|first14=Samuel S.K.|last14=Lam|first15=Alan J.|last15=Korman|first16=James P.|last16=Allison|first17=Gordon J.|last17=Freeman|first18=Arlene H.|last18=Sharpe|first19=Erika L.|last19=Pearce|first20=Ton N.|last20=Schumacher|first21=Ruedi|last21=Aebersold|first22=Hans-Georg|last22=Rammensee|first23=Cornelis J. M.|last23=Melief|first24=Elaine R.|last24=Mardis|first25=William E.|last25=Gillanders|first26=Maxim N.|last26=Artyomov|first27=Robert D.|last27=Schreiber|date=27 November 2014|journal=Nature|volume=515|issue=7528|pages=577–581|doi=10.1038/nature13988|pmid=25428507|pmc=4279952|bibcode=2014Natur.515..577G }}
• Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708{{cite journal|title=The regulatory landscape for actively personalized cancer immunotherapies|first1=Cedrik M|last1=Britten|first2=Harpreet|last2=Singh-Jasuja|first3=Bruno|last3=Flamion|first4=Axel|last4=Hoos|first5=Christoph|last5=Huber|first6=Karl-Josef|last6=Kallen|first7=Samir N|last7=Khleif|first8=Sebastian|last8=Kreiter|first9=Michaela|last9=Nielsen|first10=Hans-Georg|last10=Rammensee|first11=Ugur|last11=Sahin|first12=Thomas|last12=Hinz|first13=Ulrich|last13=Kalinke|date=8 October 2013|journal=Nature Biotechnology|volume=31|issue=10|pages=880–882|doi=10.1038/nbt.2708|pmid=24104749|s2cid=19069323}}
• Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanović S, Rammensee HG. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002 Oct 15;62(20):5818-27{{cite journal|title=Integrated functional genomics approach for the design of patient-individual antitumor vaccines|first1=Toni|last1=Weinschenk|first2=Cécile|last2=Gouttefangeas|first3=Markus|last3=Schirle|first4=Florian|last4=Obermayr|first5=Steffen|last5=Walter|first6=Oliver|last6=Schoor|first7=Raffael|last7=Kurek|first8=Wolfgang|last8=Loeser|first9=Karl-Horst|last9=Bichler|first10=Dorothee|last10=Wernet|first11=Stefan|last11=Stevanović|first12=Hans-Georg|last12=Rammensee|date=15 October 2002|journal=Cancer Research|volume=62|issue=20|pages=5818–5827|pmid=12384544}}
• Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000 Jan;30(1):1–7{{cite journal|title=In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies|first1=I.|last1=Hoerr|first2=R.|last2=Obst|first3=H. G.|last3=Rammensee|first4=G.|last4=Jung|date=1 January 2000|journal=European Journal of Immunology|volume=30|issue=1|pages=1–7|doi=10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#|pmid=10602021|s2cid=196606232 }}
• Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999 Nov;50(3-4):213-9. Review{{cite journal|title=SYFPEITHI: database for MHC ligands and peptide motifs|first1=H.|last1=Rammensee|first2=J.|last2=Bachmann|first3=N. P.|last3=Emmerich|first4=O. A.|last4=Bachor|first5=S.|last5=Stevanović|date=1 November 1999|journal=Immunogenetics|volume=50|issue=3–4|pages=213–219|pmid=10602881|doi=10.1007/s002510050595|s2cid=1407069}}
• Falk K, Rötzschke O, Stevanović S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991 May 23;351(6324):290-6.
• Rötzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee HG. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature. 1990 Nov 15;348(6298):252-4{{cite journal|title=Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules|first1=K.|last1=Falk|first2=O.|last2=Rötzschke|first3=S.|last3=Stevanović|first4=G.|last4=Jung|first5=H. G.|last5=Rammensee|date=23 May 1991|journal=Nature|volume=351|issue=6324|pages=290–296|doi=10.1038/351290a0|pmid=1709722|bibcode=1991Natur.351..290F |s2cid=4342714|doi-access=free}}
• Deres K, Schild H, Wiesmüller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989 Nov 30;342(6249):561-4{{cite journal|title=In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine|first1=K.|last1=Deres|first2=H.|last2=Schild|first3=K. H.|last3=Wiesmüller|first4=G.|last4=Jung|first5=H. G.|last5=Rammensee|date=30 November 1989|journal=Nature|volume=342|issue=6249|pages=561–564|doi=10.1038/342561a0|pmid=2586628|bibcode=1989Natur.342..561D |s2cid=4316816|doi-access=free}}

{{stack|{{portal|Biography|Biology}}}}

• Cancer immunotherapy

{{Reflist}}

{{authority control}}

{{DEFAULTSORT:Rammensee, Hans Georg}}

Category:German immunologists

Category:Living people

Category:1953 births

Category:Academic staff of the University of Tübingen